ICU Medical (ICUI) to Release Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is projected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $599.10 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

ICU Medical Price Performance

Shares of ICUI stock opened at $160.25 on Tuesday. The business has a fifty day simple moving average of $160.76 and a 200 day simple moving average of $166.28. The company has a market cap of $3.92 billion, a P/E ratio of -35.07 and a beta of 0.63. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical has a twelve month low of $93.36 and a twelve month high of $196.26.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. Finally, KeyCorp lifted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $199.67.

Insider Activity

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Christian B. Voigtlander sold 1,430 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00. The disclosure for this sale can be found here. Insiders sold a total of 15,775 shares of company stock valued at $2,548,017 over the last three months. Corporate insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.